256 related articles for article (PubMed ID: 37151353)
1. Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with
Zhu J; Zhu X; Xie F; Ding Y; Lu H; Dong Y; Li P; Fu J; Liang A; Zeng Y; Xiu B
Pathol Oncol Res; 2023; 29():1611070. PubMed ID: 37151353
[No Abstract] [Full Text] [Related]
2. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Argyropoulos KV; Palomba ML
Hematol Oncol Clin North Am; 2018 Oct; 32(5):853-864. PubMed ID: 30190023
[TBL] [Abstract][Full Text] [Related]
3. Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia.
Muñoz J; Paludo J; Sarosiek S; Castillo JJ
Cells; 2022 Oct; 11(20):. PubMed ID: 36291152
[TBL] [Abstract][Full Text] [Related]
4. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.
Sarosiek S; Sermer D; Branagan AR; Treon SP; Castillo JJ
Expert Rev Anticancer Ther; 2022 May; 22(5):471-478. PubMed ID: 35404729
[TBL] [Abstract][Full Text] [Related]
5. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Lim KJC; Tam CS
Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
[No Abstract] [Full Text] [Related]
6. Optimizing BTK Inhibition in Waldenström Macroglobulinemia.
Sarosiek S; Castillo JJ
J Natl Compr Canc Netw; 2024 May; 22(4):. PubMed ID: 38754469
[TBL] [Abstract][Full Text] [Related]
7. Case report: A rare case of coexisting Waldenstrom Macroglobulinemia and B-cell acute lymphoblastic leukemia with KMT2D and MECOM mutations.
Wang L; Tang J; Feng J; Huang Y; Cheng Y; Xu H; Miao Y
Front Immunol; 2022; 13():1001482. PubMed ID: 36325357
[TBL] [Abstract][Full Text] [Related]
8. How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.
Treon SP; Sarosiek S; Castillo JJ
Blood; 2024 Apr; 143(17):1702-1712. PubMed ID: 38211337
[TBL] [Abstract][Full Text] [Related]
9. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
Tawfiq RK; Abeykoon JP; Kapoor P
Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
[TBL] [Abstract][Full Text] [Related]
10. BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia.
Varettoni M; Matous JV
Hematol Oncol Clin North Am; 2023 Aug; 37(4):707-717. PubMed ID: 37246088
[TBL] [Abstract][Full Text] [Related]
11. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
[TBL] [Abstract][Full Text] [Related]
12. How to Sequence Therapies in Waldenström Macroglobulinemia.
Sarosiek S; Treon SP; Castillo JJ
Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
[TBL] [Abstract][Full Text] [Related]
13. A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia.
Kaedbey R; Forward N; Sehn LH; Shafey M; Doucette S; Chen CI
Curr Oncol; 2022 Sep; 29(10):7122-7139. PubMed ID: 36290837
[TBL] [Abstract][Full Text] [Related]
14. A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia.
An G; Zhou D; Cheng S; Zhou K; Li J; Zhou J; Xie L; Jin J; Zhong L; Yan L; Guo H; Du C; Zhong J; Yu Y; Wu B; Qiu L
Clin Cancer Res; 2021 Oct; 27(20):5492-5501. PubMed ID: 34253577
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
Tam CS; Ou YC; Trotman J; Opat S
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1329-1344. PubMed ID: 34491123
[No Abstract] [Full Text] [Related]
16. The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.
Gavriatopoulou M; Fotiou D; Ntanasis-Stathopoulos I; Dimopoulos MA
Expert Rev Anticancer Ther; 2020 Aug; 20(8):663-674. PubMed ID: 32631091
[TBL] [Abstract][Full Text] [Related]
17. Current approach to Waldenström macroglobulinemia.
Kapoor P; Rajkumar SV
Blood Rev; 2023 Nov; 62():101129. PubMed ID: 37659912
[TBL] [Abstract][Full Text] [Related]
18. Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Castillo JJ; Buske C; Trotman J; Sarosiek S; Treon SP
Am J Hematol; 2023 Feb; 98(2):338-347. PubMed ID: 36415104
[TBL] [Abstract][Full Text] [Related]
19. Management of Waldenström macroglobulinemia in 2020.
Castillo JJ; Treon SP
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):372-379. PubMed ID: 33275726
[TBL] [Abstract][Full Text] [Related]
20. Current approach to Waldenström Macroglobulinemia.
Ravi G; Kapoor P
Cancer Treat Res Commun; 2022; 31():100527. PubMed ID: 35149375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]